News Column

Mikulski Meets with AstraZeneca Leadership and Employees to Discuss Biotechnology Jobs in Frederick County

July 14, 2014

FREDERICK, Md., July 14 -- The office of Sen. Barbara A. Mikulski, D-Md., issued the following news release:

U.S. Senator Barbara A. Mikulski (D-Md.), a senior member of the Senate Health, Education, Labor and Pensions (HELP) Committee, today visited AstraZeneca's biologics manufacturing center in Frederick to meet with employees and hear first-hand how important Maryland biotech is to keeping families safe and healthy while also supporting hundreds of health research, innovation and manufacturing jobs in Frederick.

"In Maryland, life science is the life blood of our economy. It supports jobs developing new biological products, new pharmaceuticals and new cures that save and improve lives," Senator Mikulski said. "Here at AstraZeneca, I heard first-hand the importance of biotech in promoting community health and supporting research, innovation and manufacturing jobs here in Frederick. I'm proud to support research and innovation jobs in Maryland's biotech industry keeping our state competitive in the global economy. By working to develop safe and effective treatments, we can ensure that our nation's health care providers have the tools they need to keep families healthy."

Senator Mikulski was joined by senior representatives of AstraZeneca to discuss the role of the Frederick facility in producing innovative medicines used by millions of patients worldwide, the importance of keeping life sciences jobs in Maryland, and how to work together to make sure patients get the medicines they need to stay healthy.

As a senior member of the Senate HELP Committee, Senator Mikulski helped lead passage of the Food and Drug Administration Safety and Innovation Act, which reauthorized the prescription drug user fee program and the medical device user fee program in 2012. These programs authorize the Food and Drug Administration (FDA) to collect fees from drug, device and biotechnology companies in order to support the timely review of drug and device applications.

TNS30VitinMar-140715-4796921 30VitinMar

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Targeted News Service

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters